Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from IN8bio ( (INAB) ) is now available.
On June 24, 2025, IN8bio, Inc. received a formal notification from The Nasdaq Stock Market LLC confirming that the company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which mandates a minimum bid price of at least $1.00 per share. This compliance resolution closes the matter, potentially stabilizing IN8bio’s market position and reassuring stakeholders of its adherence to Nasdaq’s listing requirements.
The most recent analyst rating on (INAB) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on IN8bio stock, see the INAB Stock Forecast page.
Spark’s Take on INAB Stock
According to Spark, TipRanks’ AI Analyst, INAB is a Underperform.
IN8bio’s stock score reflects significant financial challenges, typical of early-stage biotechnology companies. The financial performance is hindered by substantial operational losses and reliance on external funding, while technical analysis shows bearish market trends. Valuation remains speculative with a negative P/E ratio, emphasizing the high-risk nature of investing in developmental biotech firms.
To see Spark’s full report on INAB stock, click here.
More about IN8bio
Average Trading Volume: 172,598
Technical Sentiment Signal: Sell
Current Market Cap: $7.34M
See more insights into INAB stock on TipRanks’ Stock Analysis page.